AIC
GNMK

Ameritas Investment Company’s GenMark Diagnostics, Inc GNMK Stock Holding History

Ameritas Investment Company’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,020
Closed -$43K – 954
2019
Q1 		$43K Buy
+6,020
New +$39.6K 0.01% 452

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameritas Investment Company's GNMK Position: Q2 2019 in Review

Ameritas Investment Company sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2019, closing a stake of 6,020 shares — an estimated $43K sold.

Ameritas Investment Company first reported a position in GNMK in Q1 2019 and held it in 1 quarter. The position peaked at $43K in Q1 2019. 106 funds tracked by Wall St. Rank hold GNMK as of Q2 2019.

  • Ameritas Investment Company reported no remaining GenMark Diagnostics, Inc position as of Q2 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 6,020 GenMark Diagnostics, Inc shares in Q2 2019, an estimated $43K.
  • Ameritas Investment Company first reported a position in GenMark Diagnostics, Inc in Q1 2019 and held it in 1 quarter.
  • Ameritas Investment Company's GenMark Diagnostics, Inc position peaked at $43K in Q1 2019.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2019.

Based on Ameritas Investment Company's 13F filing for Q2 2019, filed 7 Aug 2019.